Abhinav Dhall

Cell Biologist | Protein Engineer | Functional Genomics to Accelerate Drug Discovery

Role
Principal Scientist at Flagship Pioneering
Location
Boston, MA, US
LinkedIn followers
500 followers

About Abhinav Dhall

Highly motivated drug developer with 10+ years of experience in translating early discovery research to proof-of-concept stage. I am passionate about combining small-molecule screening with genetic editing and functional genomics to discover novel therapeutics for diseases. My broad scientific training includes organic chemistry, protein biochemistry, genome engineering and wet-lab assisted AI/ML models of protein engineering, which gives me a multi-faceted perspective into preclinical drug discovery. During my master’s in Chemistry, I utilized organic synthesis techniques to synthesize drug candidates for neurodegenerative diseases. The excitement of scientific discovery motivated me to pursue doctoral studies in Chemical Biology/Chemistry at the University of Washington, Seattle, where I studied the molecular mechanisms of epigenetic transcriptional regulation through biophysical analyses of nucleo-protein chromatin complexes. This work involved purification and characterization of large protein complexes, peptide synthesis, protein engineering and extensive enzymology.I joined the Cell Biology/Newborn Medicine department at Harvard Medical School/Boston Children’s Hospital in 2017 to study the epigenetic and metabolic basis of leukemia progression. My postdoctoral work was published in Nature in 2025, where we described the identification of a novel drug combination through high-throughput screening of smalI-molecule libraries, followed by mechanism of action (MoA) studies and PDX models to elucidate a new transcriptional program in WNT driven cancers. Since 2021 I have led a team of Scientists and Associate Scientists at Vor Biopharma to engineer genetically edited HSPCs and T cells for hematologic disorders. This highly cross-functional work includes leveraging human genetic databases (UKBiobank, gnomAD, DepMap, HPA) for target receptor identification, genetically engineering novel epitopes in proteins for modulating antibody-antigen interaction, utilizing AI/ML models of protein engineering and advancing candidates towards IND submission in collaboration with computational biology, translational biology and process/analytical development teams.

Experience

  1. Principal Scientist

    Flagship Pioneering

    Nov 2025 — Present · Cambridge, MA, US

Education

  • Indian Institute of Technology, Bombay

    Bachelor's degree

    2004 — 2009

  • University of Washington

    Doctor of Philosophy - PhD, Chemistry (Chemical Biology)

    2010 — 2016

  • Harvard University

    Introduction to Translational Medicine

    2017 — 2017

Skills

  • Matlab
  • Analytics
  • Data Analysis
  • Business Analysis
  • Statistics
  • Sas

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.